Vectors Conditionally Expressing Therapeutic Proteins, Host Cells Comprising the Vectors, and Uses Thereof

A method for treating a tumor in a mammal comprising:

• A) administering to the mammal at least 1.0×1011 viral particles of a vector comprising a polynucleotide encoding an ecdysone receptor-based gene switch, wherein said polynucleotide comprises:
• (1) at least one transcription factor sequence which is operably linked to a promoter, wherein said at least one transcription factor sequence encodes a ligand-dependent transcription factor, and
• (2) a polynucleotide encoding a polypeptide at least 85% identical to IL-12 operably linked to a promoter which is activated by said ligand-dependent transcription factor;
• and
• B) administering to the mammal about 5 mg of a diacylhydrazine ligand that activates the ligand-dependent transcription factor, wherein the ligand is first administered to the mammal in a time period from 24 hours before administration of vector to 24 hours following administration of vector, and wherein the ligand is administered daily for a period of 7 to 28 days.

A method for treating a tumor in a mammal comprising:

• A) administering to the mammal at least 1.0×1011 viral particles of a vector comprising a polynucleotide encoding an ecdysone receptor-based gene switch, wherein said polynucleotide comprises:
• (1) at least one transcription factor sequence which is operably linked to a promoter, wherein said at least one transcription factor sequence encodes a ligand-dependent transcription factor, and
• (2) a polynucleotide encoding a polypeptide at least 85% identical to IL-12 operably linked to a promoter which is activated by said ligand-dependent transcription factor;
• and
• B) administering to the mammal about 20 mg of a diacylhydrazine ligand that activates the ligand-dependent transcription factor, wherein the ligand is first administered to the mammal in a time period from 24 hours before administration of vector to 24 hours following administration of vector, and wherein the ligand is administered daily for a period of 7 to 28 days.

A method for treating a tumor in a mammal comprising:

• A) administering to the mammal at least 1.0×1011 viral particles of a vector comprising a polynucleotide encoding an ecdysone receptor-based gene switch, wherein said polynucleotide comprises:
• (1) at least one transcription factor sequence which is operably linked to a promoter, wherein said at least one transcription factor sequence encodes a ligand-dependent transcription factor, and
• (2) a polynucleotide encoding a polypeptide at least 85% identical to IL-12 operably linked to a promoter which is activated by said ligand-dependent transcription factor;
• and
• B) administering to the mammal about 100 mg of a diacylhydrazine ligand that activates the ligand-dependent transcription factor, wherein the ligand is first administered to the mammal in a time period from 24 hours before administration of vector to 24 hours following administration of vector, and wherein the ligand is administered daily for a period of 7 to 28 days.